Adlai Nortye ANL
NASDAQ ANL
$15.01 +0.26 (+1.76%)
At close: Sep 4, 2026 · 4:00 PM EDT

Adlai Nortye (ANL) Liabilities and Shareholders Equity (2022 - 2026)

Adlai Nortye (ANL) posted quarterly Liabilities and Shareholders Equity of $34.4 million for Q4 2025, down 51.69% year-over-year from $71.3 million in Q4 2024, and down 52.21% quarter-over-quarter from $72.0 million in Q2 2025.

Analysis

Adlai Nortye (ANL) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends

Adlai Nortye (ANL) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $34.4 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Liabilities and Shareholders Equity fell 51.69% year-over-year to $34.4 million; the TTM figure through Dec 2025 stood at $285.4 million (down 25.23% YoY), while the FY2025 annual figure was $34.4 million, down 51.69% from the prior year.
  • Liabilities and Shareholders Equity eased to $34.4 million in Q4 2025 per ANL's latest filing, from $72.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $130.2 million in Q4 2023 and bottomed at $34.4 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $81.4 million across 4 years, with a median of $72.3 million in 2022.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 79.34% — and 2025, when it sank 51.69%.
  • Adlai Nortye's Liabilities and Shareholders Equity stood at $72.6 million in 2022, then surged by 79.34% to $130.2 million in 2023, then plunged by 45.26% to $71.3 million in 2024, then plunged by 51.69% to $34.4 million in 2025.
  • Business Quant data shows ANL's Liabilities and Shareholders Equity at $34.4 million in Q4 2025, $72.0 million in Q2 2025, and $71.3 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Adlai Nortye 500.08 Mn 268.19 Mn - 248.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 248.36 Mn
Dec 31, 2025 34.43 Mn
Jun 30, 2025 72.05 Mn
Dec 31, 2024 71.27 Mn
Jun 30, 2024 107.68 Mn
Dec 31, 2023 130.19 Mn
Dec 31, 2022 72.59 Mn